These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 21602551)
1. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. Ahmad Z; Fraig MM; Pinn ML; Tyagi S; Nuermberger EL; Grosset JH; Karakousis PC J Antimicrob Chemother; 2011 Jul; 66(7):1560-6. PubMed ID: 21602551 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. Ahmad Z; Nuermberger EL; Tasneen R; Pinn ML; Williams KN; Peloquin CA; Grosset JH; Karakousis PC J Antimicrob Chemother; 2010 Apr; 65(4):729-34. PubMed ID: 20123722 [TBL] [Abstract][Full Text] [Related]
3. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473 [TBL] [Abstract][Full Text] [Related]
4. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Dutta NK; Illei PB; Peloquin CA; Pinn ML; Mdluli KE; Nuermberger EL; Grosset JH; Karakousis PC Antimicrob Agents Chemother; 2012 Jul; 56(7):3726-31. PubMed ID: 22547623 [TBL] [Abstract][Full Text] [Related]
5. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043 [TBL] [Abstract][Full Text] [Related]
7. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024 [TBL] [Abstract][Full Text] [Related]
8. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination. Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC Front Immunol; 2020; 11():680. PubMed ID: 32411131 [TBL] [Abstract][Full Text] [Related]
10. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Lenaerts AJ; Hoff D; Aly S; Ehlers S; Andries K; Cantarero L; Orme IM; Basaraba RJ Antimicrob Agents Chemother; 2007 Sep; 51(9):3338-45. PubMed ID: 17517834 [TBL] [Abstract][Full Text] [Related]
11. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure. Hu Y; Pertinez H; Liu Y; Davies G; Coates A J Antimicrob Chemother; 2019 Jun; 74(6):1627-1633. PubMed ID: 30789209 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. Montgomery SA; Young EF; Durham PG; Zulauf KE; Rank L; Miller BK; Hayden JD; Lin FC; Welch JT; Hickey AJ; Braunstein M PLoS One; 2018; 13(9):e0204495. PubMed ID: 30261007 [TBL] [Abstract][Full Text] [Related]
13. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886 [TBL] [Abstract][Full Text] [Related]
14. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. Dutta NK; Pinn ML; Zhao M; Rudek MA; Karakousis PC J Antimicrob Chemother; 2013 Jun; 68(6):1327-30. PubMed ID: 23463208 [TBL] [Abstract][Full Text] [Related]
15. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. Hoff DR; Ryan GJ; Driver ER; Ssemakulu CC; De Groote MA; Basaraba RJ; Lenaerts AJ PLoS One; 2011 Mar; 6(3):e17550. PubMed ID: 21445321 [TBL] [Abstract][Full Text] [Related]
16. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)]. Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898 [TBL] [Abstract][Full Text] [Related]
17. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model. Eckhardt E; Li Y; Mamerow S; Schinköthe J; Sehl-Ewert J; Dreisbach J; Corleis B; Dorhoi A; Teifke J; Menge C; Kloss F; Bastian M Antimicrob Agents Chemother; 2023 Apr; 67(4):e0143822. PubMed ID: 36975792 [TBL] [Abstract][Full Text] [Related]
19. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149 [TBL] [Abstract][Full Text] [Related]
20. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]